Therapeutics News and Research

RSS

Pearl advances PT003 dual combination drug candidate into Phase 2 studies for treatment of COPD

Pearl Therapeutics Inc. today announced the advancement of its dual combination product candidate, PT003 and its individual components, PT001 and PT005 into a series of planned Phase 2 studies in patients with moderate-to-severe COPD.

17 Jun 2011

Snack-based diet can increase risk of obesity

A high-fat diet can be bad for your health. However, a snack-based "cafeteria"-style diet of highly palatable, energy-dense foods is even worse, according to new research.

17 Jun 2011

CTI announces positive results from Phase I-II pixantrone combination study against INHL

Cell Therapeutics, Inc. announced the publication of results posted in the online journal of Cancer of a Phase I-II study that evaluated the safety and efficacy of pixantrone when used in combination with fludarabine, dexamethasone and rituximab replacing mitoxantrone in the standard FND-R regimen with FPD-R among 28 patients with relapsed or refractory indolent non-Hodgkin's lymphoma.

17 Jun 2011

New Australian drug shows positive response in patients with multiple myeloma blood cancer

Australian monoclonal antibody company, Immune System Therapeutics Limited (IST), today announced it would double patient recruitment in its Phase II trial for a breakthrough antibody treatment for terminal blood cancer.

16 Jun 2011

Positive results from Cubist CXA-201 and CB-183,315 Phase 2 studies for complicated intra-abdominal infections

Cubist Pharmaceuticals, Inc., a leading acute care therapeutics company, today announced positive top-line results from the recently completed Phase 2 studies of its CXA-201 and CB-183,315 antibiotic pipeline candidates. CXA-201 was studied for the treatment of complicated intra-abdominal infections (cIAI) in adults.

16 Jun 2011

Initial data from COMPLETE study on peripheral T-cell lymphoma presented at ICML 2011

Allos Therapeutics, Inc. today announced the presentation of initial data from COMPLETE, an international registry designed to address the urgent need for an increased understanding of the treatment patterns and outcomes for patients with peripheral T-cell lymphoma.

16 Jun 2011

Positive results from SKP-1041 Phase 2 study in insomnia patients with MOTN awakenings

Results of a Phase 2 study sponsored by Somnus Therapeutics, Inc., add further evidence supporting the efficacy and safety of a novel bedtime therapeutic that addresses a major underserved need of insomnia patients: maintaining sleep.

16 Jun 2011

Conference to discuss new diagnostic and treatment options for cognitive impairments in MS

On June 21-23, 2011, the New York Academy of Sciences will bring together physicians, neurologists, clinical neuropsychologists, cellular and molecular biologists and patient advocates to discuss current challenges and potential solutions for improving diagnosis, treatment and management of the cognitive symptoms of MS.

15 Jun 2011

Cardinal Health renews pharmaceutical distribution agreement with Prime Therapeutics

Cardinal Health today announced that it has signed a renewed, three-year agreement with Prime Therapeutics, one of the nation's leading pharmacy benefit managers, to continue to serve as its primary pharmaceutical supply chain partner for its mail-service pharmacy, PrimeMail®.

15 Jun 2011

Galectin strengthens cancer drug patent portfolio in Europe

Galectin Therapeutics Inc. today announced that the European Patent Office has granted the Company a new patent, No. 02731178.6, "Co-administration of a Polysaccharide with a Chemotherapy for the Treatment of Cancer".

15 Jun 2011

Researchers reveal how anti-arrhythmic drugs control irregular heartbeats

University of British Columbia researchers - using an innovative, atom-by-atom substitution method - have uncovered the mechanism by which a particular class of drugs controls irregular heartbeats.

15 Jun 2011

Bayer's submission of IND for BAY 94-9343 triggers $2M milestone payment to ImmunoGen

ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that Bayer HealthCare Pharmaceuticals' submission of an Investigational New Drug (IND) application for the TAP compound, BAY 94-9343, triggers a $2 million milestone payment to ImmunoGen.

15 Jun 2011

CTI completes pixantrone NDA resubmission meeting with FDA's Division of Oncology Drug Products

Cell Therapeutics, Inc. today announced that it met with the U.S. Food and Drug Administration's Division of Oncology Drug Products.

14 Jun 2011

Life Technologies, Fox Chase partner to provide next-generation sequencing analysis of solid tumors

Fox Chase Cancer Center, one of the nation's leading cancer research and treatment institutions, today announced it has entered into an agreement with Life Technologies Corporation that will underpin a new program to provide next-generation sequencing analysis of solid tumors.

14 Jun 2011

Positive preliminary results from CytRx bafetinib Phase 2 trial for relapsed B-cell chronic lymphocytic leukemia

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that preliminary results from its ENABLE Phase 2 proof-of-concept trial demonstrated that bafetinib, the Company's Bcr-Abl, Lyn and Fyn kinase inhibitor, was clinically active in a group of patients with relapsed or refractory B-cell chronic lymphocytic leukemia (B-CLL) who have failed several other treatments for their cancer.

13 Jun 2011

Trimeris, Synageva enter definitive merger agreement

Synageva BioPharma Corp., a privately held biopharmaceutical company developing therapeutic products for rare disorders, and Trimeris, Inc., announced today that they have entered into a definitive agreement under which Synageva will merge with Trimeris in an all-stock transaction.

13 Jun 2011

Millennium reports results from two MLN9708 ongoing Phase I studies on multiple myeloma

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today reported results from two ongoing Phase I studies with MLN9708, the first oral proteasome inhibitor being studied in patients with relapsed and/or refractory multiple myeloma.

13 Jun 2011

Quintiles, Kareus partner to advance KU-046 diabetes drug candidate into clinical trials

Kareus Therapeutics SA, the company focused on the development of novel therapeutics to address high unmet medical need, today announced a broad strategic alliance with Quintiles to progress the development of two of Kareus' pre-clinical programs through clinical trials.

13 Jun 2011

Kurma, CRT launch BliNK Therapeutics to generate monoclonal antibodies

Cancer Research Technology, the commercial arm of Cancer Research UK, and Paris-based venture capital firm, Kurma Life Sciences Partners (Kurma), have launched a spin-out company, BliNK Therapeutics Ltd, to generate monoclonal antibodies using a novel platform.

13 Jun 2011

Hyperthermia prevents repair of tumor cells

BSD Medical Corporation, a leading provider of medical systems that utilize heat therapy to treat cancer, announced today that a study published in the Proceedings of the National Academy of Sciences demonstrated that hyperthermia can be a powerful tool to inhibit the ability of cancer cells to repair the DNA damage caused by radiation or chemotherapy.

10 Jun 2011

Therapeutics News and Research

Pearl advances PT003 dual combination drug candidate into Phase 2 studies for treatment of COPD

Snack-based diet can increase risk of obesity

CTI announces positive results from Phase I-II pixantrone combination study against INHL

New Australian drug shows positive response in patients with multiple myeloma blood cancer

Positive results from Cubist CXA-201 and CB-183,315 Phase 2 studies for complicated intra-abdominal infections

Initial data from COMPLETE study on peripheral T-cell lymphoma presented at ICML 2011

Positive results from SKP-1041 Phase 2 study in insomnia patients with MOTN awakenings

Conference to discuss new diagnostic and treatment options for cognitive impairments in MS

Cardinal Health renews pharmaceutical distribution agreement with Prime Therapeutics

Galectin strengthens cancer drug patent portfolio in Europe

Researchers reveal how anti-arrhythmic drugs control irregular heartbeats

Bayer's submission of IND for BAY 94-9343 triggers $2M milestone payment to ImmunoGen

CTI completes pixantrone NDA resubmission meeting with FDA's Division of Oncology Drug Products

Life Technologies, Fox Chase partner to provide next-generation sequencing analysis of solid tumors

Positive preliminary results from CytRx bafetinib Phase 2 trial for relapsed B-cell chronic lymphocytic leukemia

Trimeris, Synageva enter definitive merger agreement

Millennium reports results from two MLN9708 ongoing Phase I studies on multiple myeloma

Quintiles, Kareus partner to advance KU-046 diabetes drug candidate into clinical trials

Kurma, CRT launch BliNK Therapeutics to generate monoclonal antibodies

Hyperthermia prevents repair of tumor cells

Advancing therapeutic biopolymer development eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News